Day: November 5, 2020

Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019Third quarter 2020 GOCOVRI® product sales of $19.0 million, a 36% increase over third quarter 2019Total paid prescriptions of 7,930, a 19% increase over third quarter 2019EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the third quarter ended September 30, 2020, and recent corporate highlights. “Adamas continues to embrace operational excellence and delivered a strong performance in a complex environment. Our employees remain steadfast in their mission to serve the patient community which is particularly vulnerable during...

SANTA MONICA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — TrueCar, Inc. (NASDAQ: TRUE) today announced its financial results for the third quarter ended September 30, 2020.Third Quarter 2020 Financial HighlightsThe following financial results reflect continuing operations only:Third quarter total revenue of $77.2 million, up 31.9% from the second quarter of 2020 and down (10.0)% from the third quarter of 2019.Record third quarter income from continuing operations of $9.6 million, or $0.09 per share, compared to loss from continuing operations of $(8.8) million, or $(0.08) per share, in the third quarter of 2019.Record third quarter Adjusted EBITDA(1) of $20.5 million, representing an Adjusted EBITDA margin(2) of 26.5%, compared to Adjusted EBITDA of $3.1 million, representing an Adjusted EBITDA margin of 3.6%, in the third quarter...

— Recovering Business Activity Led to Substantial Improvement in Gross Profit over Q2-––-Year-to Date Operating Cash Flow of $27.9MM and Free Cash Flow of $18.9MM–––-Positive New Business Momentum Reflects Scale and Demand for New Technology Offerings––CHICAGO, Nov. 05, 2020 (GLOBE NEWSWIRE) — SP Plus Corporation (Nasdaq:SP), a leading provider of technology-driven mobility solutions for aviation, commercial, hospitality and institutional clients throughout North America, today announced its third quarter and nine months 2020 results.Third Quarter CommentaryMarc Baumann, Chief Executive Officer, stated, “We continued to execute effectively within a challenging operating and business environment. Business activity rebounded significantly from this year’s second quarter, and together...

SUNNYVALE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Infinera Corporation (NASDAQ: INFN) today released financial results for its third quarter ended September 26, 2020.GAAP revenue for the quarter was $340.2 million compared to $331.6 million in the second quarter of 2020 and $325.3 million in the third quarter of 2019.GAAP gross margin for the quarter was 31.8% compared to 29.4% in the second quarter of 2020 and 26.7% in the third quarter of 2019. GAAP operating margin for the quarter was (7.9)% compared to (13.5)% in the second quarter of 2020 and (21.3)% in the third quarter of 2019.GAAP net loss for the quarter was $(35.9) million, or $(0.19) per share, compared to $(61.6) million, or $(0.33) per share, in the second quarter of 2020, and $(84.8) million, or $(0.47) per share, in the third quarter of 2019.Non-GAAP revenue for...

DUBLIN, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Giga-tronics Incorporated (OTCQB: GIGA) (the “Company”) reported results for the second quarter and six months ended September 26, 2020.Revenue for the second fiscal quarter was $2.7 million compared to $3.0 million for the second quarter of fiscal 2020.   Microsource filter sales in the second quarter decreased to $1.9 million from $2.7 million in the second quarter last year. The decrease in Microsource filter revenues was related to the delayed receipt of certain orders resulting in lower revenue recognition associated with such orders, which also reduced gross margin due to lower overhead absorption. Radar/EW test sales during the second quarter of fiscal 2021 were $820,000 versus $253,000 in the second quarter of fiscal 2020. Net loss attributable to common shareholders for the...

Q1’21 Financial Results and Recent Business HighlightsRevenue of $328.4 millionGAAP Gross Margin of 41.0 percent; non-GAAP Gross Margin of 49.7 percentGAAP diluted loss per share of $0.08; non-GAAP diluted earnings per share of $1.85Cash and short-term investments of $243.9 millionCompleted the acquisition of DisplayLink and the rights to Broadcom’s wireless IoT connectivity businessSAN JOSE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Synaptics Incorporated (NASDAQ: SYNA), today reported financial results for its first fiscal quarter ended September 26, 2020.Net revenue for the first quarter of fiscal 2021 was $328.4 million. GAAP net loss for the first quarter of fiscal 2021 was $2.8 million, or a loss of $0.08 per diluted share. Non-GAAP net income for the first quarter of fiscal 2021 was $66.7 million, or $1.85 per diluted share.“Synaptics...

– Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library “hotspot” trial –– Eden BioCell on track for IND filing in Taiwan for autologus CAR-T clinical trial this year based on rapid personalized manufacturing; several patients dosed under compassionate use –– Three abstracts accepted at Society for Neuro-Oncology, including first clinical data from phase 2 combination clinical trial with Regeneron’s Libtayo®–– Controlled IL-12 receives Rare Pediatric Disease Designantion for DIPG; all three clinical sites active in phase 1/2 pediatric brain tumor trial –– Strengthens leadership with two new Directors; Populates Scientific Advisory Board; Names former Gilead Executive Adam Levy as EVP, Investor Relations and Corporate Communications –BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc....

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results and a business update for the third quarter ended September 30, 2020.“We continue to make progress to develop our pipeline of core inhibitor candidates for the treatment of patients with HBV,” said John McHutchison, AO, MD, Chief Executive Officer and President of Assembly Biosciences. “We have made great strides toward initiating the vebicorvir Phase 3 registrational program, as well as advancing ABI-H2158 and ABI-H3733, our more potent, next-generation core inhibitor compounds, in the clinic.”Recent UpdatesHBV PortfolioVebicorvir (VBR or ABI-H0731):...

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:Cowen 2020 IO Next SummitDate: Friday, November 13, 2020Fireside chat presentation: 11:45 a.m. ETStifel 2020 Virtual Healthcare ConferenceDate: Tuesday, November 17, 2020Fireside chat presentation: 2:00 p.m. ETEvercore ISI 3rdAnnual HealthCONx ConferenceDate: Tuesday, December 1, 2020Fireside chat presentation: 9:40 a.m. ETA live audio webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com. A replay of the webcast will be archived on the website for approximately four weeks.About NkartaNkarta is a clinical-stage...

TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2020, and provided an update on its operations.Recent Corporate HighlightsOn July 21, 2020, Profound closed an underwritten offering of common shares, including the full exercise of the over-allotment option, resulting in the issuance of 3,172,414 common shares at a price of US$14.50, for gross proceeds of approximately US$46 million.As of the end of October 2020, there were six TULSA centers in the United...